Disease Landscape and Forecast Insights

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by the deficiency of clotting factor VIII. Prophylaxis, the typical care for hemophilia A patients, is especially preferred…

Hemophilia A, a monogenic X-linked recessive bleeding disorder, is caused by factor VIII deficiency. Current treatments include factor VIII recombinant therapies, bypass agents, Hemlibra, and…

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in…

The acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many…

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX (FIX). Individuals with this condition experience prolonged bleeding. Prescribing options include factor balancing…

Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by a deficiency in factor VIII. Currently, FVIII recombinant therapies, bypass agents, Hemlibra, and vasopressin receptor…

Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…

Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…

Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…